CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is currently the biggest discovery in life science. As a precise gene editing tool, it has been widely used in many areas with a great potential to treat human diseases. While some CRISPR-based therapeutic studies are moving to clinical trials, CRISPR's therapeutic promise was brought into question when some issues were found that could become major obstacles in moving the great genome editing tools to the clinic.
While many groups are actively resolving these obstacles, the significant challenges to minimize the immunological risks and avoid potential tumorgenicity have received more attention as big concerns for CRISPR-Cas therapeutics advancing toward the clinic.
We believe it is timely to summarize and analyze the emerging immunological risk and potential tumorgenicity with the CRISPR-Cas systems, to predict how this exciting genome editing market will affect other related segments of the entire life science market in the next few years. We also hope our opinion could serve as a ""crowd crystal"" on those discussions in response to the issues, and bring a better market environment for the technology to be sharpened and advanced into clinical applications.
The Report Includes:
Detailed understanding of the two major types of adaptive immunity to Cas9 proteins, i.e. humoral immunity and cell-mediated immunity
Comparison of in vivo and ex vivo CRISPR-Cas9 therapy and discussion about clinical safety and probability to enter human clinical trials
Coverage of technical areas such as protein engineering and metagenomic analysis as driving forces to new CRISPR-Cas system discovery
A look into the oncogenic risks by CRISPR-Cas9 genome editing and studies on the development and implementation of genetic systems designed to toggle tumor suppressor genes off and back-on again
Key Topics Covered:
Chapter 1 CRISPR Cas Genome Editing: Therapeutic or Thwarted by Preexisting Human Immunity?
Immunogenicity Risk
Potential Solutions to Overcome Preexisting Immunity to Cas Proteins in Humans
Dynamics Communities and Community Summit North America, in collaboration with Microsoft, are introducing the Biz Apps Partner Summit to run July 24-25, 2024, in Bellevue, Washington delivering a 24-hour immersion into FY 25 priorities, opportunities...
E-Textile Market is Segmented by Type (Passive Electronic Textiles, Active Electronic Textiles, Ultra-Electronic Textiles), by Application (Military Uses, Civil Uses, Healthcare Uses).
The Global E-Textile Market size is expected to reach USD 5238.3...
Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development...
Hinkal, a multi-chain privacy layer for confidential decentralized finance (DeFi) transactions, today announced a $1.4 million strategic funding round led by SALT Fund, with participation from Draper Associates, SNZ and Peer VC. Additionally, Tal...
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients.
"It's critical for providers...
In an effort to provide the best service possible, enterprise developer Interfuse, has added several important improvements to its Knowledge Base application. Within this update, new pages accessible in the Knowledge Base include Recently Added,...